Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate.

Hirotaka MiyashitaChristina CruzVaibhav Patel

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2021)

The incidence of SREs in patients with bone metastatic prostate cancer may be higher in those with history of SREs, Gleason ≥ 7, and elevated serum ALP.

Keyphrases

prostate cancer
risk factors
radical prostatectomy
squamous cell carcinoma
small cell lung cancer
bone mineral density
soft tissue
bone regeneration
bone loss
drug induced
smoking cessation